AA
NBIX icon

ALPS Advisors’s Neurocrine Biosciences NBIX Stock Holding History

ALPS Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,246
Closed -$460K – 1100
2025
Q4 		$460K Buy
3,246
+36
+1% +$5.21K ﹤0.01% 792
2025
Q3 		$451K Buy
+3,210
New +$435K ﹤0.01% 797
2025
Q1 		– Sell
-2,901
Closed -$396K – 1082
2024
Q4 		$396K Hold
2,901
– – ﹤0.01% 697
2024
Q3 		$334K Buy
2,901
+410
+16% +$56.2K ﹤0.01% 909
2024
Q2 		$343K Sell
2,491
-15
-0.6% -$2.06K ﹤0.01% 758
2024
Q1 		$346K Sell
2,506
-409
-14% -$55.9K ﹤0.01% 851
2023
Q4 		$384K Sell
2,915
-165
-5% -$19K ﹤0.01% 705
2023
Q3 		$347K Buy
+3,080
New +$324K ﹤0.01% 670
2020
Q3 		– Sell
-2,542
Closed -$310K – 902
2020
Q2 		$310K Sell
2,542
-282
-10% -$31.2K ﹤0.01% 551
2020
Q1 		$244K Buy
+2,824
New +$276K ﹤0.01% 591
2017
Q2 		– Sell
-74,944
Closed -$3.25M – 781
2017
Q1 		$3.25M Sell
74,944
-8,538
-10% -$366K 0.02% 156
2016
Q4 		$3.23M Sell
83,482
-27,113
-25% -$1.23M 0.02% 151
2016
Q3 		$5.6M Sell
110,595
-11,139
-9% -$555K 0.05% 132
2016
Q2 		$5.53M Buy
121,734
+24,508
+25% +$1.13M 0.05% 122
2016
Q1 		$3.85M Sell
97,226
-16,325
-14% -$648K 0.04% 127
2015
Q4 		$6.42M Sell
113,551
-20,860
-16% -$1.06M 0.06% 115
2015
Q3 		$53.5K Buy
134,411
+49,638
+59% +$2.4M 0.06% 109
2015
Q2 		$4.05M Buy
84,773
+43,292
+104% +$1.84M 0.03% 130
2015
Q1 		$1.65M Buy
+41,481
New +$1.48M 0.01% 158

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's NBIX Position: Q1 2026 in Review

ALPS Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,246 shares — an estimated $460K sold.

ALPS Advisors first reported a position in NBIX in Q1 2015 and held it in 19 quarters. The position peaked at $6.42M in Q4 2015. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • ALPS Advisors reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • ALPS Advisors sold 3,246 Neurocrine Biosciences shares in Q1 2026, an estimated $460K.
  • ALPS Advisors first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 19 quarters.
  • ALPS Advisors's Neurocrine Biosciences position peaked at $6.42M in Q4 2015.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.